Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Hypertension

• Publication date

  2004-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00004872-200409000-00022PMID 15311106
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosiglitazone Activates Renal Sodium- and Water-Reabsorptive Pathways and Lowers Blood Pressure in Normal Rats

  2004cited by this paper
• Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients.

  2003cited by this paper
• Rosiglitazone lowers blood pressure and increases arterial compliance in postmenopausal women with type 2 diabetes.

  2003cited by this paper
• Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus

  2003cited by this paper
• The prevention of type 2 diabetes--lifestyle change or pharmacotherapy? A challenge for the 21st century.

  2003cited by this paper
• Rosiglitazone reduces urinary albumin excretion in type II diabetes

  2003cited by this paper
• Addressing the insulin resistance syndrome: a role for the thiazolidinediones.

  2002cited by this paper
• HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study.

  2002cited by this paper
• Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution.

  2002cited by this paper
• A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

  2002cited by this paper
• Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records.

  2002cited by this paper
• Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study.

  2002cited by this paper
• The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.

  2002cited by this paper
• Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.

  2002cited by this paper
• Differentiating members of the thiazolidinedione class: a focus on safety

  2002cited by this paper
• The metabolic syndrome and related cardiovascular risk

  2001cited by this paper
• The role of SGK1 in hormone-regulated sodium transport.

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001cited by this paper
• Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes.

  2001cited by this paper
• Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension.

  2001cited by this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE

  2001cited by this paper
• Effects of a low‐energy diet and an insulin‐sensitizing agent on ambulatory blood pressure in overweight hypertensive patients

  2000cited by this paper
• The euglycemic hyperinsulinemic clamp examination: variability and reproducibility.

  2000cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Guidelines for the management of hypertension.

  2000cited by this paper
• Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

  2000cited by this paper
• Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study.

  2000cited by this paper
• Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation.

  1999cited by this paper
• The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats.

  1999cited by this paper
• 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

  1999cited by this paper
• Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus.

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes

  1999cited by this paper
• How to measure insulin sensitivity

  1998cited by this paper
• Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM

  1997cited by this paper
• Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat.

  1997cited by this paper
• Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits.

  1997cited by this paper
• Risk Variable Clustering in the Insulin Resistance Syndrome: The Framingham Offspring Study

  1997cited by this paper
• Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system.

  1996cited by this paper
• A comparison of the hypotensive and hypoglycaemic actions of an angiotensin converting enzyme inhibitor, an AT1a antagonist and troglitazone

  1996cited by this paper
• Special feature: what is a normal blood pressure in ambulatory monitoring?

  1996cited by this paper
• Why bioelectrical impedance analysis should be used for estimating adiposity.

  1996cited by this paper
• Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.

  1996cited by this paper
• What is a normal blood pressure on ambulatory monitoring

  1996cited by this paper
• State of the Market: A Review of Ambulatory Blood Pressure Monitoring Devices

  1995cited by this paper
• Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

  1995cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Performance characteristics of the HemoCue B-Glucose analyzer using whole-blood samples.

  1993cited by this paper
• Performance characteristics of the hemoCue B-glucose analyzer using whole-blood samples

  1993cited by this paper
• Comparison of the HemoCue beta-glucose photometer and reflotron for open heart surgery.

  1993cited by this paper
• Relationship between insulin release, antinatriuresis and hypokalaemia after glucose ingestion in normal and hypertensive man.

  1993cited by this paper
• Effects of ciglitazone on blood pressure and intracellular calcium metabolism.

  1993cited by this paper
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial

  1993cited by this paper
• The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension.

  1993cited by this paper
• Comparison of the HemoCue β-Glucose Photometer and Reflotron for Open Heart Surgery

  1993cited by this paper
• Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease

  1991cited by this paper
• Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

  1990cited by this paper
• Insulin resistance in essential hypertension.

  1990cited by this paper
• Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

  1990cited by this paper
• Banting lecture 1988. Role of insulin resistance in human disease.

  1988cited by this paper
• Role of Insulin Resistance in Human Disease

  1988cited by this paper
• Insulin resistance in essential hypertension.

  1987cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper
• Effects of arterial versus venous sampling on analysis of glucose kinetics in man.

  1976cited by this paper

• Effects of oral antidiabetic agents on the renin–angiotensin–aldosterone system

  2025cites this paper
• IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW

  2022cites this paper
• Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study

  2021cites this paper
• Hypertension in Children with Type 2 Diabetes or the Metabolic Syndrome

  2017cites this paper
• Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes

  2016cites this paper
• Hypertension in type 2 diabetes: impact of glucose-lowering medications

  2016cites this paper
• Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis

  2014cites this paper
• Treatment with thiazolidinediones

  2013cites this paper
• Prolonged Induction Activates Cebpα Independent Adipogenesis in NIH/3T3 Cells

  2013cites this paper
• Hypertension in Children with the Metabolic Syndrome or Type 2 Diabetes

  2013cites this paper
• Rosiglitazone/Metformin

  2012cites this paper
• Association of insulin resistance with arterial stiffness in nondiabetic peritoneal dialysis patients

  2012cites this paper
• Current Antidiabetic Therapies and Mechanisms

  2011cites this paper
• Diabetic nephropathy – Epidemiology in Asia and the current state of treatment

  2011cites this paper
• Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.

  2011cites this paper
• Advances in the treatment of type 2 diabetes mellitus.

  2011cites this paper
• Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats.

  2011cites this paper
• Reprint of: Thiazolidinediones for the treatment of type 2 diabetes

  2011cites this paper
• Relation between the estimated glomerular filtration rate and pulse wave velocity in Japanese.

  2010cites this paper
• A double‐blind, placebo‐controlled trial of rosiglitazone for clozapine‐induced glucose metabolism impairment in patients with Schizophrenia

  2009cites this paper
• Effects of thiazolidinediones beyond glycaemic control.

  2009cites this paper
• Suppression of retinal peroxisome proliferator-activated receptor gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase.

  2009cites this paper
• Arterial stiffness in patients with non-diabetic chronic kidney disease (CKD).

  2009cites this paper
• Reduced cardiotropic response to insulin in spontaneously hypertensive rats: role of peroxisome proliferator-activated receptor-γ-initiated signaling

  2008cites this paper
• An association between decreased estimated glomerular filtration rate and arterial stiffness.

  2008cites this paper
• Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes.

  2008cites this paper
• Augmentation of nitric oxide is crucial for the time-dependent effects of rosiglitazone on blood pressure and baroreflex function in rats

  2008cites this paper
• Thiazolidinediones: Antidiabetic Drugs with Cardiovascular Effects

  2008cites this paper
• Cardiovascular risk and cardiometabolic protection: role of glitazones.

  2008cites this paper
• Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update

  2008cites this paper
• [One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].

  2008cites this paper
• The Sympatho-Adrenal System in the Metabolic Syndrome

  2008cites this paper
• Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians.

  2008cites this paper
• PPAR-γ, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches

  2008cites this paper
• Fatty acid and glucose metabolism in upper body obesity : effects of diet and exercise compared to pioglitazone administration

  2007cites this paper
• Pioglitazone shift circadian rhythm of blood pressure from non‐dipper to dipper type in type 2 diabetes mellitus

  2007cites this paper
• Hipertensión arterial y dislipemia asociadas a diabetes mellitus. Papel de los PPAR. Enfoque terapéutico

  2007cites this paper
• Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes

  2007cites this paper
• Efectos pleiotrópicos de telmisartán en el paciente diabético

  2007cites this paper
• Pioglitazone Decreases Ambulatory Blood Pressure in Type 2 Diabetics With Difficult‐to‐Control Hypertension

  2007cites this paper
• Thiazolidinediones and vascular damage

  2007cites this paper
• Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1‐year treatment in non‐diabetic subjects with insulin resistance

  2007cites this paper
• Reading and citing from the Journal of Hypertension.

  2007cites this paper
• Renoprotective Effects of Rosiglitazone in Stroke-Prone Spontaneously Hypertensive Rats

  2007cites this paper
• Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists

  2007cites this paper
• La diabetes mellitus tipo 2 como enfermedad cardiovascular

  2007cites this paper
• Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study

  2007cites this paper
• Future directions for insulin sensitizers in disease prevention.

  2007cites this paper
• Thiazolidinediones for the treatment of type 2 diabetes.

  2007cites this paper
• Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.

  2007cites this paper
• Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

  2007cites this paper
• Treatment of obesity with diet/exercise versus pioglitazone has distinct effects on lipoprotein particle size.

  2006cites this paper
• Metabolički sindrom, kao sindrom savremenog društva, odlikuju sledeće komponente: abdomenska gojaznost, dislipi demija, arterijska hipertenzija, hiperglikemija, hiperinsulinemija, odnosno rezistencija na insulin, disfunkcija bubre

  2006cites this paper
• Rosiglitazone is effective and well‐tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes

  2006cites this paper
• Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF‐α levels in Type 2 diabetic patients: a randomized study

  2006cites this paper
• Thiazolidinediones

  2006cites this paper
• The effects of thiazolidinediones on blood pressure levels – A systematic review

  2006cites this paper
• Metabolic syndrome in the elderly

  2006cites this paper
• Thiazolidinediones: antidiabetic drugs with cardiovascular effects.

  2006cites this paper
• Thiazolidinediones and Progression of Renal Disease in Patients with Diabetes

  2006cites this paper
• A Meta‐Analysis of the Effect of Thiazolidinediones on Blood Pressure

  2006cites this paper
• Management of hypertension in children and adolescents with the metabolic syndrome.

  2006cites this paper
• Can PPARgamma agonists have a role in the management of obesity-related hypertension?

  2006cites this paper
• The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy

  2006cites this paper
• Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.

  2006cites this paper
• Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

  2006cites this paper
• Hipertensión arterial y riesgo cardiovascular en el año 2004

  2005cites this paper
• Prediabetes - The New Target for Primary Prevention of Cardiovascular Metabolic Dysfunction

  2005cites this paper
• The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension.

  2005cites this paper
• The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.

  2005cites this paper
• Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes

  2005cites this paper
• Antihypertensive treatment and new-onset diabetes mellitus

  2005cites this paper
• Insulin Resistance Is Associated with Arterial Stiffness in Nondiabetic Hypertensives Independent of Metabolic Status

  2005cites this paper
• Addressing the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Metabolic Syndrome in the Southeastern United States, Part II: Treatment Recommendations for Management of the Global Cardiovascular Risk of Hypertension, Dyslipidemia, Diabetes Mellitus, and the Meta

  2005cites this paper
• Management of hypertension and diabetes: Treatment goals, drug choices, current practice, and strategies for improving care

  2005cites this paper
• PPARa agonists: killing two birds with one stone?

  2004cites this paper
• PPARgamma agonists: killing two birds with one stone?

  2004cites this paper